Acurx Pharmaceuticals, Inc. (ACXP)

Acurx Pharmaceuticals' stock has experienced a significant decline over the past six months. Key events impacting the stock price include the Q4 2025 earnings report, which announced a net loss despite beating analyst EPS expectations, an anticipated delay in FDA approval for ibezapolstat, and presentations and business updates. The company announced its Q4 2025 earnings, reporting a net loss of $1.6 million for the quarter and $8.0 million for the full year 2025. Alliance Global reportedly slashed its price target on Acurx due to pushing back the expected FDA approval of ibezapolstat for C. difficile infection to 2031 from 2028. The company has announced scientific poster presentations and plans to present at healthcare company showcases and investor summits in April and May 2026.

There is no indication of demand seasonality for Acurx Pharmaceuticals, Inc.'s products and services. Demand for its antibiotics is primarily driven by the prevalence of bacterial infections, which do not exhibit strong seasonal patterns.

Acurx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing new antibiotics to combat difficult-to-treat bacterial infections. Their approach involves creating Gram-positive selective spectrum antibiotics that target and block the active site of the Gram-positive specific bacterial enzyme DNA polymerase IIIC, inhibiting DNA replication. The company's primary product candidates include ibezapolstat, an orally administered drug in Phase 2b clinical trials for the treatment of Clostridioides difficile infection, and ACX-375C, being developed as a potential treatment targeting various Gram-positive bacteria.

Acurx Pharmaceuticals, Inc. is headquartered in Staten Island, New York, United States. The company develops antibiotics for use in the United States and plans to advance ibezapolstat into international Phase 3 clinical trials, indicating a focus on the U.S. market with aspirations for a broader global reach.

Acurx Pharmaceuticals' brand reputation is influenced by its clinical trial progress and financial performance. Positive clinical data presentations have been made for ibezapolstat. However, the significant decline in stock price and underperformance relative to the broader US Biotechs industry and the overall US Market suggest challenges in investor confidence. The anticipated multi-year delay in FDA approval for ibezapolstat could also negatively impact its reputation. Analysts have maintained a "Strong Buy" consensus rating with a high price target.

Acurx Pharmaceuticals, Inc. has a notable institutional and individual ownership structure. Institutional investors own 11.53% of the stock, while individual insiders hold 20.30%. The general public owns 89.4% of the shares. Major institutional shareholders include Millennium Management Llc, Vanguard Group Inc, and Northern Trust Corp.